Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4

Authors


  • Potential conflict of interest: Nothing to report.

No abstract is available for this article.

Ancillary